Publication | Open Access

Studies leading to the identification of ZD1839 (iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

Molecular PharmacologyDrug TargetingOncologyMedicineReceptor Tyrosine KinaseCancer GrowthPharmacotherapyAnti-cancer AgentCancer TreatmentPharmacologyCell BiologyCancer ResearchDrug Discovery